Aging is a process accompanied by progressive decline in cellular function. Our aim is to create a groundbreaking therapy based on patented proteins, that rejuvenate elderly cells, all while maintaining their distinct properties.
Onassis Holdings Corp is a company dedicated to finding, investing in, and developing solutions for regenerative medicine, longevity, rejuvenation, and anti-aging. Currently, it operates a subsidiary named Ananda Labs, Inc., a U.S. startup headquartered in New York City with an office in Tel Aviv. Established in 2023, Ananda Labs has developed the RPER platform, based on 10 years of research at the Hebrew University of Jerusalem. This innovative, state-of-the-art platform uses patented factors to reverse aging by 50% and significantly impact longevity.
Ananda Labs is focused on pioneering research and development and is planning to raise funds to revolutionize the field of medicine, with the goal of curing diseases and conditions that previously had no solutions or only symptomatic treatments. We offer an exceptional opportunity for accredited investors to participate.
Onassis Holdings Corp, a Nevada-based company, is in the process of raising funds via a Reg A+ offering, also known as a “mini IPO.” The company is managed by a highly skilled team in science, medicine, and finance.
Our technology was developed based on extensive scientific research published in prestigious, high-impact journals from the Nature, Science, and Cell publishing groups.
Ananda Labs Inc. is at the forefront of epigenetic reprogramming for longevity and anti-aging, developed in partnership with the Hebrew University of Jerusalem.
Ananda Labs is creating advanced therapeutics centered on epigenetic reprogramming to combat human diseases and promote anti-aging.
This involves altering gene expression without changing the DNA sequence, using epigenetic editors—a potentially revolutionary advancement in the medical and wellness industry.
Ananda Labs has a superior and safer set of patented factors compared to competitors, providing a significant advantage. Competitors’ valuations range from hundreds of millions to a few billion dollars, all being in the R&D stage.
Onassis and Ananda Labs hold exclusive licensing rights to several key patents, including the method for reprogramming human cells.
We aim to rejuvenate fibroblast cells by 40%-50% of their age to provide long-lasting skin elasticity and a healthy, younger appearance. Our research will focus on:
Short term goal
Long term goal
Request password by email: info@ananda-labs.com